After two rejections, FDA approves AstraZeneca potassium drug

May 21, 2018

After two previous rejections, the FDA has approved AstraZeneca’s excess potassium drug, Lokelma.

AstraZeneca bought the drug’s original developer, ZS Pharma, for $2.7 billion in 2015. The drug was rejected twice by the FDA — once in May 2016 and again in March 2017 — due to unspecified manufacturing issues.

The approval is a big one for AstraZeneca, as it will give the drugmaker a rival hyperkalemia drug to Vifor Pharma’s Veltassa.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments